Related Experiment Video
Updated: Feb 4, 2026

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
Published on: November 3, 2023
Selective prophylactic solvent-detergent plasma and cryoprecipitate transfusion to prevent intraventricular
S Al-Abdi1, K Dabelah1, T Mousa1
1King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Science, Department of Pediatrics, King Abdulaziz Hospital, Ministry of National Guard Hospital, Al-Ahsa, Saudi Arabia.
Insights
Selective prophylactic transfusion of solvent-detergent plasma and cryoprecipitate within 12 hours of life may reduce intraventricular hemorrhage (IVH) in extreme preterm infants (EPI). Further trials are needed to confirm benefits and risks.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
- Clinical Research
Background:
- Intraventricular hemorrhage (IVH) is a significant concern in extreme preterm infants (EPI).
- Evidence is conflicting regarding the efficacy of prophylactic coagulation factor transfusion in preventing IVH in EPI within the first hours of life (HOL).
Purpose of the Study:
- To evaluate the effectiveness of selective prophylactic solvent-detergent plasma and cryoprecipitate transfusion (SP-SDP/Cryoprecipitate-T) within 12 hours of life in preventing IVH in EPI.
- To compare IVH rates between a period of selective prophylactic transfusion and a period of rescue transfusion.
Main Methods:
- Retrospective analysis of prospectively collected data from a Saudi tertiary neonatal intensive care unit.
- Case-historical control study comparing EPI born during 2010-2013 (SP-SDP/Cryoprecipitate-T period) with those born during 2006-2009 (rescue SDP/Cryoprecipitate-T period).
Main Results:
- The IVH rate was significantly lower in the selective prophylactic transfusion period (30.8%) compared to the rescue transfusion period (51.2%).
- The observed difference in IVH rates remained statistically significant after adjusting for six other identified IVH risk factors (OR 0.42, 95% CI 0.21-0.88, p=0.02).
Conclusions:
- Early selective prophylactic transfusion of solvent-detergent plasma and cryoprecipitate may decrease the incidence of IVH in extreme preterm infants.
- A large multicenter clinical trial is warranted to definitively establish the short- and long-term benefits and risks of this intervention.
- Institutions with high IVH rates may consider early selective prophylactic transfusion pending further evidence.
Background:
Contradictory evidence exists whether a prophylactic coagulation factor transfusion in the first hours of life (HOL) prevents intraventricular hemorrhage (IVH) in extreme preterm infants (EPI, <28 weeks gestation). We aimed to determine whether selective prophylactic solvent-detergent plasma and cryoprecipitate transfusion within 12 hours of life (SP-SDP/Cryoprecipitate-T) could prevent IVH in EPI.
Method:
This is a retrospective analysis, case-historical control, of prospectively collected data from a pre-existing electronic neonatal database at a Saudi tertiary neonatal intensive care unit. We compared the IVH rate in EPI born in the first 4 years (Jan 2010-Dec 2013) of the SP-SDP/Cryoprecipitate-T period with that of EPI born during the last 4 years (Jan 2006-Dec 2009) of the rescue SDP/Cryoprecipitate-T period.
Results:
The IVH rate was lower in the SP compared to the rescue- SDP/Cryoprecipitate-T period (30.8% versus 51.2%, odds ratio 0.42, 95% confidence interval 0.21, 0.88, p = 0.02). This difference remained significant after controlling for six other IVH risk factors.
Conclusions:
Early SP-SDP/Cryoprecipitate-T may reduce the IVH rate in EPI. A large multicenter clinical trial is required for confirm the short and long-term benefit and risk of this intervention. Until then, early SP-SDP/Cryoprecipitate-T may be considered by an institution with a persistently high IVH rate.
Related Concept Videos
Solvents
A...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Titration in Nonaqueous Solvents
Detergent Purification of Membrane Proteins
Cancer Prevention
Some...

